Likely just bc we are still waiting on data. Regardless will become a different conversation when they have data in hand from upcoming lipid/nash drug. And we still technically get the secondaries of the sarm at some point, there may be some real gems in that stuff, regardless of levels of statistical significance... stuff that will help to define phase 3 and indication stuff and population sizes etc of treatable folks. Anyways, lipid data will remove the need for analysts in the short term... positive lipid data comparable to mdgl would make it pretty easy for most people to then connect the dots, correlate 1:1 our data to the mdgl data, and draw a value comparison... Our valuations now generally build in various percentages of chance that trial x or y or z will fail etc. I think if you gave the analyst a hypothetical “if VKTX upcoming phase 2 showed results in line with mdgl (not even better, which is possible like anything else)- what would be your target price...”. Then I think it would be numbers we would relate to. I’m not a stockbroker by trade. But this offering was exactly what was needed imho. No joke. But my guess is, that when people start throwing 55 million at your company without new data being available, your brand is possibly finally catching on ? maybe. Usually it takes great news to get a deal like that. Somebody bought our cow without waiting to taste the milk. Anyways, more and bigger fish in the game now, we may see a fair valuation sooner than we thought. Friday volume was something totally new. I think the price will need to be 1-2 dollars higher at least to make the option trading more logical and profitable, so I’m assuming we sit between possibly 7 and 8’s until real news. All just wild guesses. If the secondary data is kind on the sarm and we are even marginal or better on lipid stuff, I’d want 12.00 for my shares, given our strongly strengthened financial position and the terms on which they would be able to negotiate on partnering deals. But again, these are old calculations, based on the world of Viking before the massive volume day and financial security we just got. I’d love to see a partner deal or two and then to see the company focus its remaining abilities on bringing the rest of the pipeline on-line, and letting a bigger partner shoulder the phase 3 dance with the fda. Wouldn’t care if they went alone either, but they clearly have been capable of success in early phase trials, and this later stage stuff will be time and money consuming to someone. If partner occurs on decent terms for either compound, the sky is the limit perhaps.
Here’s to dreaming buddy!
